1 Adalimumab (Humira),, a tumor necrosis factor (TNF)-α inhibitor, was approved by the FDA in 2015 to treat HS. 1 Prior to its approval, patients with HS relied on surgery to remove the skin ...

Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients with hidradenitis suppurativa ... response after 12 weeks," Del ...

Biotech stock MoonLake Immunotherapeutics rose Monday after the company said ... with the standard of care, Humira. But Belanger notes about 35% of HS patients take Humira for less than six ...

Serum C-reactive protein is being investigated as a biomarker to predict adalimumab response in hidradenitis suppurativa patients ... suppurativa—it is sold as Humira by AbbVie in the US ...